Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Loading Strategies With Antiplatelet Drugs in Patients Undergoing Elective Coronary Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with biomarker negative stable or unstable angina pectoris~* Written informed consent~* In women with childbearing potential a pregnancy test is obligatory~Exclusion Criteria:~* Age \< 18 years and \>80 years~* ST-elevation MI~* Elevated cardiac biomarkers~* Subjects with known contraindications to clopidogrel treatment, which are hypersensitivity to the drug substance or any component of the product and active pathological bleeding such as peptic ulcer or intracranial hemorrhage and with known severe liver disease (Child Pugh Class C)~* Subjects with known contraindications to prasugrel treatment, which are hypersensitivity to the drug substance or any component of the product, active pathological bleeding such as peptic ulcer or intracranial hemorrhage and a history of prior transient ischemic attack (TIA) or stroke and with known severe liver disease (Child Pugh Class C)~* Chronic therapy on potent P2Y12 receptor inhibitors (ticagrelor, prasugrel)~* Pre-treatment with a loading dose of either clopidogrel, prasugrel or ticagrelor~* Simultaneous participation in another clinical trial that involves the administration of an investigational medicinal drug within 30 days prior to the start of this clinical trial~* Major surgeries in the last 6 weeks and planned surgeries within the next 6 weeks (per decision of the treating physician)~* Active bleeding~* Known or persistent abuse of medication, drugs or alcohol~* Current or planned pregnancy or nursing women, women 90 days after childbirth. Females of childbearing potential, who do not use and are not willing to use medically reliable methods of contraception for the entire study duration (such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices) unless they are surgically sterilized / hysterectomized or there are any other criteria considered sufficiently reliable by the investigator in individual cases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Prasugrel (Type: EXPERIMENTAL): single-dose loading with 60 mg of prasugrel pre PCI
- Clopidogrel (Type: ACTIVE_COMPARATOR): loading with 600 mg of clopidogrel pre PCI

Based on this trial design, predict the completion outcome and termination type (if applicable).